Bryan Garnier strengthens its healthcare expertise with a five-person team led by Uli Kinzel

LONDON AND MUNICH, 3 OCTOBER 2024 –  Bryan, Garnier & Co, the leading investment bank for healthcare and technology-related companies, today announces that a five-person team from the M&A and strategy firm goetzpartners, led by Uli Kinzel, will join the pan-European investment bank. Uli Kinzel will become a Partner and, as Head of Healthcare Europe, will support the further expansion of the European healthcare practice from the Munich office.

As Managing Director at goetzpartners, Kinzel built up the pan-European advisory business in the pharmaceutical and healthcare sectors over the past ten years, leading teams in Munich and London. Most recently, he was responsible for several significant sector transactions, including Autolus Therapeutics’ strategic cell therapy collaboration with BioNTech, the venture debt and equity financing of digital health start-up Smart Reporting, and the acquisition of Medgate Teleklinik by OTTO. Prior to that, he led Nomura Code’s Continental European Lifesciences business after co-founding the British investment bank Code Securities, which was acquired by the Japanese banking group in 2005.

Kinzel will be joined by his former team colleague Dr. Josefine Böhm (Vice President) from goetzpartners, who will be based in the Munich office of Bryan, Garnier & Co. She most recently worked as an Investment Associate at a Munich-based impact investor and previously spent five years advising on M&A transactions and financing at Goldman Sachs in Frankfurt.

Three additional team members from Kinzel’s group are moving to Bryan, Garnier’s London office – Youchen Xin (Vice President), Alexandra Walsh, and Edoardo Nappi (Analysts). Youchen Xin, an oncologist with an MBA, has worked on numerous ECM and M&A transactions with life sciences companies at goetzpartners over the past six years, most recently as an Associate Director.

“As we embark on the next phase of growth for our pan-European healthcare platform, we are excited to join forces with Kinzel and his team,” said Hervé Ronin, Partner and Head of Global Healthcare. “Together, we are poised to take our platform to the next level. We share the same passion for healthcare and a common DNA to be the trusted advisor for leading healthcare growth companies in Germany and across Europe.”

“We are delighted to have such an experienced healthcare banker and his established team joining us,” added Falk Müller-Veerse, Partner and Head of Bryan, Garnier & Co.’s German business. “We currently see a lot of potential in Germany, especially in the pharma, biotech, and medtech sectors.”

Advising healthcare companies has been one Bryan Garnier’s core competencies for decades, including advising RNA pioneers Moderna and BioNTech on several financing rounds and IPOs, and most recently advising vaccine group Valneva as Joint Global Coordinator and Joint Bookrunner on its Euronext capital increase.

“In my more than twenty years in healthcare banking, I have had numerous points of contact with Bryan, Garnier & Co. The bank’s life sciences expertise is well known throughout the industry, and I look forward to working with colleagues whom I have known and respected for a long time,” said Uli Kinzel.